Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DINA-002
- Development stage
- Preclinical
- Lead developer
- DiNAQOR
- Modality
- Gene Therapies
- Administration
- Parenteral (noted As Loco-regional Perfusion For Kidney)
01
Overview
DINA-002 is a gene therapy candidate developed by DiNAQOR for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and has also been referenced in the context of cardiomyopathies. The drug utilizes a gene transference mechanism, aiming to deliver therapeutic genetic material to target tissues. It is classified as a gene therapy and urologic agent. As of early 2023–2025, its highest development status is preclinical or research stage with no regulatory approvals yet reported[1][2][4]. The delivery platform may involve loco-regional perfusion of the kidney for targeted administration[2][4].
- Other names
- DINAK 002DINAK002DINAK-002
Beyond the preview
Go deeper on DINA-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DINA-002.